APA (7th ed.) Citation

Medin, C., Turgeon, M., Keilson, J., Shah, S., Agopian, V., Magliocca, J., . . . Abouljoud, M. (2022). What Is the Optimal Bridging Therapy for Patients with Hepatitis C-associated Hepatocellular Carcinoma Awaiting Liver Transplant? An Analysis of the United States HCC Liver Transplantation Consortium. HPB (1365-182X), 24, S78. https://doi.org/10.1016/j.hpb.2022.05.142

Chicago Style (17th ed.) Citation

Medin, C., et al. "What Is the Optimal Bridging Therapy for Patients with Hepatitis C-associated Hepatocellular Carcinoma Awaiting Liver Transplant? An Analysis of the United States HCC Liver Transplantation Consortium." HPB (1365-182X) 24 (2022): S78. https://doi.org/10.1016/j.hpb.2022.05.142.

MLA (9th ed.) Citation

Medin, C., et al. "What Is the Optimal Bridging Therapy for Patients with Hepatitis C-associated Hepatocellular Carcinoma Awaiting Liver Transplant? An Analysis of the United States HCC Liver Transplantation Consortium." HPB (1365-182X), vol. 24, 2022, p. S78, https://doi.org/10.1016/j.hpb.2022.05.142.